XXII

#5049
22nd Century Group, Inc - Common Stock
2.4 6 USD
+0.08%
Market Price
Settore: Beni di Consumo Difensivi
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.42
2.46
Intervallo Annuale
0.27
7.32
Variazione giornaliera
+7.89%
Variazione Mensile
-45.21%
Variazione di 6 mesi
-38.35%
Variazione Annuale
-56.84%
Chiusura Precedente
2.2 8
Open
2.4 2
Minimo
2.4 2
Massimo
2.4 6
Volume
6
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, 01 Sep 2026
22Nd Century Group, Inc. current report, 01 September 2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
22Nd Century Group, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
22Nd Century Group, Inc. quarterly report, Q1 FY2026
10-Q

22Nd Century Group, Inc. current report, 03 April 2019

Full document

Business Context and Reporting Period

This Form 8-K was filed by 22nd Century Group, Inc. on April 3, 2019. The filing reports the entry into a Material Definitive Agreement with KeyGene N.V. regarding collaborative research on the Cannabis Sativa L. plant.

Key Financial Metrics

The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to the new agreement:

  • Total Agreement Value: $6,000,000 to be paid over an initial five-year term.
  • Payment Structure: A portion of the payment is contingent on KeyGene achieving specific milestone deliverables.
  • Royalties: The Company will pay royalties to KeyGene for commercialization within the Cannabis field; KeyGene will pay royalties to the Company for commercialization outside this field.

Material Changes

The primary material change is the execution of a Framework Collaborative Research Agreement with KeyGene N.V. Key terms include:

  • Exclusivity: KeyGene agreed to work exclusively with the Company regarding the Cannabis Sativa L. plant for an initial term of five years, with an option for a two-year extension.
  • Intellectual Property: The Company will exclusively own all results and intellectual property generated from the collaboration within the defined field.
  • Licensing: KeyGene received a license to commercialize results outside the Cannabis field.

Guidance, Outlook, and Risks

Management Commentary: The Company issued a press release on April 9, 2019, announcing this strategic partnership to advance its research in the cannabis sector.

Risks and Contingencies: The agreement includes customary termination provisions for both parties. The financial obligation is partially contingent on the achievement of milestone deliverables by KeyGene.

Unusual Items: None reported beyond the new contractual obligation.

Investor Verification Checklist

  • Verify the specific milestone deliverables required to trigger the contingent portion of the $6,000,000 payment.
  • Review the full text of the Framework Collaborative Research Agreement (to be filed as an exhibit to the next Form 10-Q) for detailed royalty rates and termination clauses.
  • Confirm the Company's current cash position to assess its ability to fund the initial payments under the agreement.
  • Monitor future press releases for updates on the progress of the collaboration with KeyGene N.V.

Notizie